Orchard Therapeutics PLC
Elisa Agostini, PhD, PMP has extensive experience in project management roles within the pharmaceutical and biotech industry. Elisa began their career at the University of Portsmouth as an Erasmus student in 2008, followed by a role as a Master Student at Fondazione Bruno Kessler. Elisa then continued their academic journey at LMU - Ludwig-Maximilians-Universität München as a PhD student. In 2015, they transitioned to industry, joining Sanofi as an R&D Project Leader and Head of Laboratory. Elisa later moved to Lonza as a Program Manager before assuming a Program Manager position at Cell and Gene Therapy Catapult in 2020. Currently, they hold the role of Senior Project Manager in CMC Lifecycle Management and Associate Director of Global CMC Project Management at Orchard Therapeutics.
Elisa Agostini earned their MPharm degree in Pharmacy from Università degli Studi di Padova in 2010. Elisa then went on to pursue a PhD in Pharmaceutical Technology at Ludwig-Maximilians-Universität München. In 2018, they obtained their Project Management Professional (PMP) certification from PMI-OC Project Management Institute Orange County Chapter. Elisa also holds an Italian State Exam, making their a licensed Pharmacist since 2010.
This person is not in any teams
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.